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nism is unclear, based on these re-
sults, we conclude that formalde-
hyde has a detrimental effect on
plasma RNA detection. Irrespective
of the extraction protocol used, it
appears that no amplifiable RNA in
plasma can be obtained from formal-
dehyde-treated whole-blood sam-
ples.
References
1. Lo YMD, Hjelm NM, Fidler C, Sargent IL, Murphy
MF, Chamberlain PF, et al. Prenatal diagnosis of
fetal RhD status by molecular analysis of mater-
nal plasma. N Engl J Med 1998;339:1734–8.
2. Chiu RWK, Lau TK, Leung TN, Chow KCK, Chui
DHK, Lo YMD. Prenatal exclusion of  thalas-
saemia major by examination of maternal
plasma. Lancet 2002;360:998–1000.
3. Zhong XY, Laivuori H, Livingston JC, Ylikorkala
O, Sibai BM, Holzgreve W, et al. Elevation of
both maternal and fetal extracellular circulating
deoxyribonucleic acid concentrations in the
plasma of pregnant women with preeclampsia.
Am J Obstet Gynecol 2001;184:414–9.
4. Ng EKO, Leung TN, Tsui NBY, Lau TK, Panesar
NS, Chiu RWK, et al. The concentration of
circulating corticotropin-releasing hormone
mRNA in maternal plasma is increased in pre-
eclampsia. Clin Chem 2003;49:727–31.
5. Lo YMD, Tein MS, Lau TK, Haines CJ, Leung TN,
Poon PM, et al. Quantitative analysis of fetal
DNA in maternal plasma and serum: implica-
tions for noninvasive prenatal diagnosis. Am J
Hum Genet 1998;62:768–75.
6. Dhallan R, Au WC, Mattagajasingh S, Emche S,
Bayliss P, Damewood M, et al. Methods to
increase the percentage of free fetal DNA re-
covered from the maternal circulation. JAMA
2004;291:1114–9.
7. Chung GTY, Chiu RWK, Chan KCA, Lau TK, Leung
TN, Lo YMD. Lack of dramatic enrichment of fetal
DNA in maternal plasma by formaldehyde treat-
ment. Clin Chem 2005;51:655–8.
8. Lo YMD, Chiu RWK, Chan KCA, Chung GTY.
Free fetal DNA in maternal circulation. JAMA
2004;292:2835.
9. Tsui NBY, Ng EKO, Lo YMD. Stability of endoge-
nous and added RNA in blood specimens, serum,
and plasma. Clin Chem 2002;48:1647–53.
10. Ng EKO, Tsui NBY, Lau TK, Leung TN, Chiu
RWK, Panesar NS, et al. mRNA of placental
origin is readily detectable in maternal plasma.
Proc Natl Acad Sci U S A 2003;100:4748–53.
11. Ding J, Ichikawa Y, Ishikawa T, Shimada H.
Effect of formalin on extraction of mRNA from a
formalin-fixed sample: a basic investigation.
Scand J Clin Lab Invest 2004;64:229–35.
Grace T.Y. Chung1
Rossa W.K. Chiu1
K.C. Allen Chan1
Tze K. Lau2
Tse N. Leung2
Lin W. Chan2
Y.M. Dennis Lo1*
Departments of
1 Chemical Pathology and
2 Obstetrics and Gynaecology
The Chinese University of Hong Kong
Prince of Wales Hospital
Shatin, New Territories
Hong Kong SAR, China
*Address correspondence to this au-
thor at: Department of Chemical Pathol-
ogy, The Chinese University of Hong
Kong, Prince of Wales Hospital, 30-32
Ngan Shing St., Shatin, New Territories,
Hong Kong Special Administrative Re-
gion, China. Fax 852-2194-6171; e-mail
loym@cuhk.edu.hk.
DOI: 10.1373/clinchem.2004.045807
Paraprotein Interference in an Assay
of Conjugated Bilirubin
To the Editor:
Artifactually increased total bilirubin
and artifactually low HDL have been
described recently in a patient with
a monoclonal IgM paraprotein (1 ).
Similar interferences have already
been described for serum samples
containing paraproteins when tested
for bilirubin [with a reagent from the
same manufacturer (2 )], phosphate
(3–7), creatinine (8 ), calcium (9 ),
urea nitrogen (10 ), iron (11 ), C-reac-
tive protein, and antistreptolysin-O
(12 ). Here we describe interference
in the measurement of conjugated
bilirubin by a different analyzer in
sera from 3 patients (A, B, and C)
with IgG-–type myeloma. Conju-
gated bilirubin was initially mea-
sured with the Olympus AU2700 au-
tomated analyzer using the Olympus
conjugated bilirubin assay. For pa-
tient A (40-year-old man), the re-
ported conjugated bilirubin was 37.5
mg/L, total bilirubin was 2.0 mg/L
(reference interval, 0.0–11.0 mg/L),
and total protein was 156 g/L with a
monoclonal IgG- component at a
concentration of 104.1 g/L. For pa-
tient B (64-year-old man), the re-
ported conjugated bilirubin was 12.0
mg/L, total bilirubin was 3.3 mg/L,
and total protein was 89 g/L with
a monoclonal IgG- component of
25.9 g/L. For patient C (42-year-old
woman), the reported conjugated bil-
irubin was 10.9 mg/L, total bilirubin
was 2.0 mg/L, and total protein was
136 g/L with a monoclonal IgG-
component at a concentration of 97.2
g/L. The concentration of the para-
proteins was determined by serum
protein electrophoresis with densi-
tometry and total protein measure-
ment. No spurious creatinine, cal-
cium, inorganic phosphate, urea
nitrogen, or iron measurement using
Olympus assays on the Olympus
AU2700 analyzer were detected in
the 3 samples.
The Olympus serum total bilirubin
assay is an end-point chromogenic
assay (13 ). The reagent contains an
“accelerator” (caffeine) to solubilize
unconjugated bilirubin, together with
a diazonium salt (2,5 dichlorophe-
nyl-diazonium-tetrafluoroborate), in
the presence of surfactant to avoid
protein precipitation, in a weakly
acid medium (pH 5). The color (pink)
intensity of the azobilirubin pro-
duced is proportional to the total
bilirubin concentration. For determi-
nation of the conjugated fraction, the
solubilizing agent and the surfactant
are lacking in the reagent, and the
medium is strongly acidic (pH 1) to
eliminate conjugated isomers of bili-
rubin from measurement. At this
low pH, proteins typically precipi-
tate. To avoid that precipitation, this
reagent contains a “protein stabiliz-
ing agent”. Visually, the patient sam-
ples were nonicteric and showed no
evidence of hemolysis or lipemia.
Clinically, the patients were not jaun-
diced, and there was no supporting
evidence for hemolysis or liver dis-
ease. On a different analyzer that
uses the dry-chemistry methodology
(Vitros 950; Ortho-Clinical Diagnos-
tics), the results for conjugated bili-
rubin were 0.6, 1.0, and 0.4 mg/L in
patients A, B, and C, respectively.
We also compared results between
intact sera and the serum ultrafil-
trates (Ultrafree CL; nominal molec-
ular mass cutoff, 30 kDa; Millipore)
from the same 3 patients. Serum
from a patient without myeloma and
a comparable concentration of conju-
gated bilirubin was included as a
control. The conjugated bilirubin
concentrations in the serum ultrafil-
trates were 0.9, 0.6, and 0.3 mg/L for
patients A, B, and C, respectively. No
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effect was observed in the serum
from the control patient (1.0 mg/L
before and 0.9 mg/L after ultrafiltra-
tion).
To examine the mechanism of
the interference, we performed the
Olympus assay manually for sam-
ples from the 3 patients. All volumes
were increased accordingly, with
the sample/reagent ratio specified
by the manufacturer maintained. A
white insoluble precipitate was seen
but no color change. These findings
suggest that the most likely cause of
the interference was the monoclonal
immunoglobulin, which precipitates
at very low pH (pH 1) in the absence
of surfactant. The stabilizing agent
may prevent visible, interfering pre-
cipitation of usual concentrations of
serum proteins, but not of the much
higher concentrations of certain pro-
teins, such as those generated by the
myeloma described here.
The incidence of immunoglobulin
interfering with the Olympus conju-
gated bilirubin assay appears to be
very low. Of the 200 serum sam-
ples containing a monoclonal protein
tested for conjugated bilirubin dur-
ing the year 2004, only the 3 reported
here showed an erratic behavior.
A concentration of conjugated bil-
irubin higher than that of total bili-
rubin may suggest the presence of a
monoclonal immunoglobulin. In pa-
tients in whom the quantification of
conjugated bilirubin is clinically rel-
evant, the test may be performed on
serum ultrafiltrate.
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Paraprotein Interference in Automated
Chemistry Analyzers
To the Editor:
We read with interest the Technical
Brief by Smogorzewska et al. (1 ) de-
scribing an artificially increased total
bilirubin in a patient with a monoclo-
nal IgM paraprotein. Monoclonal
paraproteins have been shown to
artifactually influence several auto-
mated assays of different methodol-
ogies, including nephelometry, turbi-
dometry, and immunologic assays,
by forming precipitates during the
assay procedure (2–7). The total bil-
irubin assay on the Hitachi 917 auto-
matic chemistry analyzer (Roche Di-
agnostics) has been reported to yield
falsely increased bilirubin values as a
result of paraprotein interference
(1, 8 ).
Smogorzewska et al. (1 ) and Pan-
tanowitz et al. (8 ) described this ar-
tifact as rare, but we have identified 6
patients at 2 hospitals with docu-
mented paraproteins who had falsely
increased serum total bilirubin. No-
tably, patients with artifactually high
total serum bilirubin had direct bili-
rubin values within the reference in-
terval. Smogorzewska et al. (1 ) and
others have hypothesized that the
Roche solubilizing agent is the cause
of the error because this interference
is absent in the direct bilirubin assay.
This is yet to be confirmed, however,
and there is no evidence from the
literature addressing the nature of
precipitate formation.
We manually performed the Roche
assay on a serum sample from a
patient with a documented parapro-
tein (100 g/L), reportedly increased
total serum bilirubin (106 mg/L),
and no clinical suspicion of liver dis-
ease or obstruction (Fig. 1). We per-
formed the assay in its entirety and
found that precipitate began to form
minutes after addition of Reagent 2.
We also found that addition of Re-
agent 1 alone caused the formation of
precipitate, but at a slower rate (90
min). No precipitate formed without
the addition of Reagent 1. This find-
ing supports the hypothesis by
Smogorzewska et al. (1 ) and others
that precipitation may be induced by
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